A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

A new Phase I clinical trial from London Health Sciences Centre Research Institute (LHSCRI) has found high-precision ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

BriaCell Therapeutics Corp. (BCTX, BCTXW) is down by 4.71 percent during Monday morning trading, following the announcement of a ...

Medically reviewed by Aleesha Grier, PsyD Metastatic breast cancer affects people in many ways. The symptoms experienced by ...

BriaCell Therapeutics (TSX:BCT) is reporting that the first metastatic breast cancer patient treated with its Bria-OTS ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...